SCHEDULE 13G/A: BlackRock Discloses 8.4% Stake in ANAPTYSBIO INC Through Latest SEC Filing
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.4% of ANAPTYSBIO INC's common stock as of December 31, 2024.
Summary
- BlackRock, Inc. filed Amendment No. 7 to Schedule 13G regarding its beneficial ownership in ANAPTYSBIO INC.
- As of December 31, 2024, BlackRock, Inc. beneficially owns 2,548,468 shares of ANAPTYSBIO INC common stock.
- This ownership represents 8.4% of the total outstanding common stock of ANAPTYSBIO INC.
- BlackRock holds sole voting power over 2,449,053 shares and sole dispositive power over 2,548,468 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- BlackRock, Inc. is classified as a parent holding company (HC) for the purpose of this filing.
- Several BlackRock subsidiaries, including BlackRock Fund Advisors, are identified as entities through which the beneficial ownership is held, with BlackRock Fund Advisors specifically noted as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment. It does not contain positive or negative performance data or forward-looking statements about the issuer.
Future Outlook
NA. This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding ANAPTYSBIO INC's future performance or BlackRock's future investment intentions beyond the scope of passive ownership.
Industry Context
NA. This Schedule 13G filing is a routine disclosure of a significant ownership stake by an institutional investor and does not provide analysis of broader industry trends or competitive landscape for ANAPTYSBIO INC.
Stakeholder Impact
- For shareholders of ANAPTYSBIO INC, BlackRock's significant 8.4% stake indicates a major institutional investor's continued interest in the company, which could be viewed as a sign of confidence.
- The filing confirms BlackRock's passive investment intent, stating the shares are not held for the purpose of changing or influencing control of the issuer, which may reassure existing management and other shareholders regarding governance stability.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney that was revoked by the new one. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end for beneficial ownership calculation). |
| 2025-01-21 | Date of execution of the new Power of Attorney by BlackRock, Inc. |
| 2025-02-05 | Date of filing of this Schedule 13G Amendment No. 7. |
Keywords
BlackRock, ANAPTYSBIO INC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Equity Stake, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.